Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CA | P42336 | 3/20 | 0.47 |
| ▸ | DHFR | P00374 | 4/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | MITF | O75030 | 1/20 | 0.46 |
| ▸ | TP53 | P04637 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | BLM | P54132 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | BRAF | P15056 | 1/20 | 0.45 |
| ▸ | MAP3K5 | Q99683 | 1/20 | 0.45 |
| ▸ | KIT | P10721 | 6/20 | 0.45 |
| ▸ | DYRK1A | Q13627 | 3/20 | 0.43 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.43 |
| ▸ | DYRK1B | Q9Y463 | 2/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4064225 | 0.81 | PIK3CA (0.47) | PIK3CAKITDYRK1AAAK1DYRK1B | |
| SCHEMBL4062147 | 0.80 | EGFR (0.61) | MAPTBRAF | |
| SCHEMBL4074235 | 0.80 | NOS1 (0.48) | PIK3CAKITDYRK1ADYRK1B | |
| SCHEMBL4063917 | 0.78 | PIK3CA (0.54) | PIK3CAKITDYRK1ADYRK1B | |
| SCHEMBL4069149 | 0.77 | APP (0.58) | DHFRMEN1MAPTKMT2AAAK1 | |
| SCHEMBL4071579 | 0.76 | EGFR (0.55) | PIK3CAMEN1TP53MAPTKMT2A | |
| SCHEMBL4069132 | 0.76 | APP (0.59) | MEN1MAPTKMT2A | |
| SCHEMBL4524104 | 0.74 | MAPT (0.46) | DHFRMEN1MITFTP53POLB | |
| SCHEMBL4070207 | 0.73 | GAK (0.48) | PIK3CAKITDYRK1ADYRK1B | |
| SCHEMBL4071679 | 0.71 | NOS1 (0.69) | PIK3CAMEN1KMT2ADYRK1ADYRK1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090036430-A1 | PYRIDO(3,2-D)PYRIMIDINES AND PHARMACEUTICAL COMPOSITIONS USEFUL FOR MEDICAL TREATMENT | 4 AZA IP NV (BE) | 2009-02-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090036430-A1 | PYRIDO(3,2-D)PYRIMIDINES AND PHARMACEUTICAL COMPOSITIONS USEFUL FOR MEDICAL TREATMENT | PNPO, TYMP, PNP | PIK3CA 1172/4885DHFR 16/4885MEN1 3783/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.